vs
STANDARD BIOTOOLS INC.(LAB)与Legacy Housing Corp(LEGH)财务数据对比。点击上方公司名可切换其他公司
Legacy Housing Corp的季度营收约是STANDARD BIOTOOLS INC.的1.3倍($25.5M vs $19.6M),Legacy Housing Corp净利率更高(32.2% vs -177.4%,领先209.6%),STANDARD BIOTOOLS INC.同比增速更快(-11.5% vs -30.6%),Legacy Housing Corp自由现金流更多($15.7M vs $-23.1M),过去两年Legacy Housing Corp的营收复合增速更高(-9.1% vs -12.2%)
Standard BioTools(原Fluidigm公司)是一家美国生命科学工具企业,主营流式细胞术与组织成像分析用质谱流式系统,以及配套的检测试剂盒与试剂,同时供应自动化基因组分析仪器、各类微流控芯片(又称集成流体电路)及配套试剂耗材,全系列产品及应用场景均可提供定制检测方案与相关服务。
Legacy Housing Corp是美国知名的经济型预制住宅、微型住宅及配套居住单元制造商,主要面向北美中低收入消费群体,提供可定制住房解决方案、配套建材及相关售后服务,服务个人及社区开发类客户。
LAB vs LEGH — 直观对比
营收规模更大
LEGH
是对方的1.3倍
$19.6M
营收增速更快
LAB
高出19.1%
-30.6%
净利率更高
LEGH
高出209.6%
-177.4%
自由现金流更多
LEGH
多$38.8M
$-23.1M
两年增速更快
LEGH
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $19.6M | $25.5M |
| 净利润 | $-34.7M | $8.2M |
| 毛利率 | 48.5% | 26.4% |
| 营业利润率 | -168.5% | 40.4% |
| 净利率 | -177.4% | 32.2% |
| 营收同比 | -11.5% | -30.6% |
| 净利润同比 | -28.8% | -43.5% |
| 每股收益(稀释后) | $-0.09 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
LAB
LEGH
| Q4 25 | — | $25.5M | ||
| Q3 25 | $19.6M | $28.8M | ||
| Q2 25 | $21.8M | $38.4M | ||
| Q1 25 | $40.8M | $24.3M | ||
| Q4 24 | — | $36.7M | ||
| Q3 24 | $22.1M | $30.2M | ||
| Q2 24 | $22.5M | $31.7M | ||
| Q1 24 | $45.5M | $30.8M |
净利润
LAB
LEGH
| Q4 25 | — | $8.2M | ||
| Q3 25 | $-34.7M | $8.6M | ||
| Q2 25 | $-33.5M | $14.7M | ||
| Q1 25 | $-26.0M | $10.3M | ||
| Q4 24 | — | $14.5M | ||
| Q3 24 | $-26.9M | $15.8M | ||
| Q2 24 | $-45.7M | $16.2M | ||
| Q1 24 | $-32.2M | $15.1M |
毛利率
LAB
LEGH
| Q4 25 | — | 26.4% | ||
| Q3 25 | 48.5% | 20.2% | ||
| Q2 25 | 48.8% | 32.4% | ||
| Q1 25 | 48.4% | 29.2% | ||
| Q4 24 | — | 27.3% | ||
| Q3 24 | 54.9% | 29.2% | ||
| Q2 24 | 46.1% | 31.9% | ||
| Q1 24 | 53.1% | 33.6% |
营业利润率
LAB
LEGH
| Q4 25 | — | 40.4% | ||
| Q3 25 | -168.5% | 33.7% | ||
| Q2 25 | -118.1% | 43.8% | ||
| Q1 25 | -80.8% | 47.7% | ||
| Q4 24 | — | 42.3% | ||
| Q3 24 | -120.9% | 50.8% | ||
| Q2 24 | -134.5% | 50.6% | ||
| Q1 24 | -132.2% | 54.3% |
净利率
LAB
LEGH
| Q4 25 | — | 32.2% | ||
| Q3 25 | -177.4% | 30.0% | ||
| Q2 25 | -153.7% | 38.3% | ||
| Q1 25 | -63.8% | 42.3% | ||
| Q4 24 | — | 39.5% | ||
| Q3 24 | -122.0% | 52.4% | ||
| Q2 24 | -203.3% | 51.1% | ||
| Q1 24 | -70.6% | 49.1% |
每股收益(稀释后)
LAB
LEGH
| Q4 25 | — | $0.38 | ||
| Q3 25 | $-0.09 | $0.35 | ||
| Q2 25 | $-0.09 | $0.60 | ||
| Q1 25 | $-0.07 | $0.41 | ||
| Q4 24 | — | $0.59 | ||
| Q3 24 | $-0.07 | $0.64 | ||
| Q2 24 | $-0.12 | $0.65 | ||
| Q1 24 | $-0.27 | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $8.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $528.6M |
| 总资产 | $539.6M | $580.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
LAB
LEGH
| Q4 25 | — | $8.5M | ||
| Q3 25 | $129.4M | $13.6M | ||
| Q2 25 | $158.6M | $2.6M | ||
| Q1 25 | $150.9M | $3.4M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $210.6M | $570.0K | ||
| Q2 24 | $269.8M | $60.0K | ||
| Q1 24 | $287.1M | $621.0K |
总债务
LAB
LEGH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益
LAB
LEGH
| Q4 25 | — | $528.6M | ||
| Q3 25 | $399.7M | $521.6M | ||
| Q2 25 | $424.5M | $512.8M | ||
| Q1 25 | $454.6M | $503.7M | ||
| Q4 24 | — | $494.0M | ||
| Q3 24 | $489.3M | $479.3M | ||
| Q2 24 | $510.3M | $463.2M | ||
| Q1 24 | $577.3M | $450.4M |
总资产
LAB
LEGH
| Q4 25 | — | $580.3M | ||
| Q3 25 | $539.6M | $557.9M | ||
| Q2 25 | $557.0M | $552.0M | ||
| Q1 25 | $579.6M | $544.6M | ||
| Q4 24 | — | $534.2M | ||
| Q3 24 | $681.5M | $521.4M | ||
| Q2 24 | $708.7M | $514.9M | ||
| Q1 24 | $777.7M | $510.0M |
负债/权益比
LAB
LEGH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $19.0M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $15.7M |
| 自由现金流率自由现金流/营收 | -118.1% | 61.6% |
| 资本支出强度资本支出/营收 | 4.5% | 13.1% |
| 现金转化率经营现金流/净利润 | — | 2.32× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $28.2M |
8季度趋势,按日历期对齐
经营现金流
LAB
LEGH
| Q4 25 | — | $19.0M | ||
| Q3 25 | $-22.2M | $7.2M | ||
| Q2 25 | $-20.7M | $6.1M | ||
| Q1 25 | $-30.3M | $4.9M | ||
| Q4 24 | — | $7.9M | ||
| Q3 24 | $-27.9M | $13.8M | ||
| Q2 24 | $-39.0M | $3.5M | ||
| Q1 24 | $-62.5M | $10.8M |
自由现金流
LAB
LEGH
| Q4 25 | — | $15.7M | ||
| Q3 25 | $-23.1M | $5.1M | ||
| Q2 25 | $-22.6M | $3.7M | ||
| Q1 25 | $-35.3M | $3.6M | ||
| Q4 24 | — | $6.0M | ||
| Q3 24 | $-30.1M | $9.1M | ||
| Q2 24 | $-41.0M | $1.7M | ||
| Q1 24 | $-63.3M | $9.9M |
自由现金流率
LAB
LEGH
| Q4 25 | — | 61.6% | ||
| Q3 25 | -118.1% | 17.8% | ||
| Q2 25 | -103.6% | 9.6% | ||
| Q1 25 | -86.6% | 15.0% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | -136.4% | 30.2% | ||
| Q2 24 | -182.2% | 5.4% | ||
| Q1 24 | -138.9% | 32.2% |
资本支出强度
LAB
LEGH
| Q4 25 | — | 13.1% | ||
| Q3 25 | 4.5% | 7.1% | ||
| Q2 25 | 8.7% | 6.2% | ||
| Q1 25 | 12.4% | 5.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 10.2% | 15.6% | ||
| Q2 24 | 8.6% | 5.5% | ||
| Q1 24 | 1.7% | 2.8% |
现金转化率
LAB
LEGH
| Q4 25 | — | 2.32× | ||
| Q3 25 | — | 0.83× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 0.54× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
LEGH
| Commercial Sales | $8.6M | 34% |
| Retail Store Sales | $6.0M | 24% |
| Inventory Finance Sales | $5.0M | 20% |
| Direct Sales | $4.4M | 17% |
| Other | $1.5M | 6% |